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Abstract
Purpose—Wnt pathways control key biological processes that potentially impact on tumour
progression and patient survival. We aimed to evaluate DNA methylation at promoter CpG islands
(CGIs) of Wnt pathway genes in ovarian tumours at presentation and identify biomarkers of
patient progression-free survival (PFS).
Experimental Design—Epithelial ovarian tumours (screening study n=120, validation study
n=61) prospectively collected through a cohort study, were analysed by differential methylation
hybridisation (DMH) at 302 loci spanning 189 promoter CGIs at 137 genes in Wnt pathways. The
association of methylation and progression free survival was examined by Cox proportional
hazards model.
Results—DNA methylation is associated with PFS at 20/302 loci (p<0.05, n=111), with 5 loci
significant at FDR<10%. 11/20 loci retain significance in an independent validation cohort
(n=48,p≤0.05,FDR≤10%), and 7 of these loci, at FZD4, DVL1, NFATC3, ROCK1, LRP5, AXIN1
and NKD1 genes, are independent from clinical parameters (adjusted p<0.05). Increased
methylation at these loci associates with increased hazard of disease progression. A multivariate
Cox model incorporates only NKD1 and DVL1, identifying two groups differing in PFS
(HR=2.09; 95%CI (1.39, 3.15); permutation test p<0.005). Methylation at DVL1 and NFATC3
show significant association with response. Consistent with their epigenetic regulation, reduced
expression of FZD4, DVL1 and ROCK1 is an indicator of early disease relapse in an independent
ovarian tumour cohort (n=311, adjusted p<0.05).
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Conclusions—The data highlights the importance of epigenetic regulation of multiple promoter
CGIs of Wnt pathway genes in ovarian cancer and identifies methylation at NKD1 and DVL1 as
independent predictors of PFS.
Introduction
Epithelial ovarian cancer (EOC) is the most lethal of all the gynaecological cancers
accounting for 52% of all gynaecological cancer-related deaths (1). Patients with advanced
disease have surgical cytoreduction followed by platinum-based chemotherapy, but there is
a low 5-year survival rate of <30% (1-5). There is a need to identify key pathways in ovarian
cancer whose activity is associated with patient survival to assist our understanding of the
molecular basis of disease progression and to identify biomarkers of sufficient
discriminatory prognostic and predictive power to be of clinical value. The established
prognostic factors of EOC at clinical presentation before primary chemotherapy are residual
disease and patient age, as well as histology, stage and grade of tumour (5-7), however those
clinical factors do not provide insights into biological mechanisms for the clinical
progression of tumours. Although many individual biomarkers in EOC have been
investigated (8-14), currently only two serum biomarkers CA125 and HE4 have been
approved by the FDA for monitoring patients with EOC (15). Identifying robust biomarkers
of patient survival following conventional treatment of EOC will also provide a solid basis
for characterising potential predictive biomarkers to novel treatment strategies and hence for
stratification of patients for targeted care in clinical practice.
Aberrant DNA methylation frequently occurs in cancer, particularly at regions generally
unmethylated in normal cells, known as CpG islands (CGIs). CGIs often co-localise with the
promoters of genes and promoter hypermethylation is associated with repression of gene
transcription (16). Several studies have shown that CGI methylation has potential as a
biomarker for monitoring tumour progression (17) and is associated with platinum-based
chemoresistance in EOC (18, 19). However, many of these studies are either limited by
small sample size or lack of validation of the methylation biomarker as an independent
prognostic marker.
The Wnt pathways control a variety of biological processes including cell proliferation,
differentiation and migration, and have a crucial role in development and tissue homeostatis
(20, 21). Wnt signalling is transduced through binding of Wnt molecules to the
transmembrane Frizzled receptor proteins (Fz) and activation of downstream signalling
pathways depending on the interaction between Wnt molecules and their specific receptors.
In the ‘canonical’ pathway, binding of Wnt molecules to Frizzled/LRP transmembrane
receptor complex results in dishevelled phosphorylation and inhibition of Axin, Gsk3b and
APC complex, subsequently allowing β-catenin to accumulate in the nucleus and interact
with transcription factors of the T-cell-specific transcription factor/lymphoid enhancer
binding factor (TCF/LEF) family (22-24). Although mutations of APC and β-catenin are
frequently observed in colorectal cancer (25, 26), they are rare in EOC (24, 27), with the
exception of endometrioid subtypes (28). Among numerous non-canonical pathways, Wnt/
planar cell polarity (PCP) signalling and Wnt/Ca2+ signalling are involved in tumourigenesis
(29-31).
In cancers where Wnt pathway gene mutations are rare, the Wnt pathway can become
disregulated through epigenetic mechanisms, such as promoter hypermethylation
(32-34).The Wnt pathway extracellular inhibitors, such as SFRPs family and WIF1, are
frequently silenced by promoter hypermethylation in cancers including EOC (33, 35-40).
However, promoter methylation of the Wnt pathway has not been comprehensively studied
in EOC. Our aim was to systematically profile DNA methylation at promoter CGIs of Wnt
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pathway genes and evaluate their role in tumour progression by assessing their association
with patient progression-free and overall survival in EOC in a prospective cohort study.
Materials and Methods
Patients
Tumour biopsies were prospectively collected in an ongoing Scottish Gynaecology Clinical
Trial Group (SGCTG)/National Cancer Research Institute (NCRI) cohort study since 1997.
Tumours included were restricted to those from patients with confirmed EOC treated with
cytoreductive surgery and platinum-based chemotherapy, excluding mucinous and clear cell
tumours. These latter histological tumour types were excluded due to their different clinical
outcome from more common serous and endometrioid EOC (41, 42). Macroscopically
normal ovarian tissue taken adjacent to the tumour, and from tissue adjacent to benign
ovarian cysts and tumours were also collected. The information about progression and
survival status of patients is obtained monthly for the first two years after chemotherapy,
subsequently 6 monthly for five years and annually thereafter. Progression free survival
(PFS) was defined as the time from first line chemotherapy to progressive disease or early
death due to EOC or other causes. Overall survival (OS) was defined as the time from first
line chemotherapy to death due to EOC or other causes. Response was measured by
RECIST 1.0 criteria. The primary objective of the cohort study is to prospectively examine
the association of DNA methylation with PFS. Secondary objectives are to examine for
association of DNA methylation with overall survival and response to treatment. The study
is approved by the MREC for Scotland (reference number 01/165). Genomic DNA was
extracted for methylation analysis as previously described (43).
Differential methylation hybridisation (DMH)
Samples were assayed in duplicates by DMH, as previous described (44). Briefly, DNA was
digested with MseI, ligated to an end-linker and divided into two aliquots. One aliquot was
mock-treated, the other aliquot was digested with the methylation-sensitive restriction
enzyme McrBC which cuts (G/A)mCN40-3000(G/A)mC (45, 46). PCR amplification was
performed with primers binding to the end-linkers, the amplicons were then labelled with
Cy3 or Cy5 and hybridised to the custom-designed 60mer-microarrays fabricated using
Agilent SurePrint Tehcnology (Agilent, UK). Labelling of DNA, array hybridisation and
image scanning was done by Oxford Gene Technology (Oxford, UK) according to the
standard Agilent aCGH protocol.
The raw signal intensities were extracted by Agilent feature extraction (v9.5.3.1). Probes
with high background noise (about 3%) were treated as missing data points and imputed by
KNN algorithm (k=10) (47, 48). Probes with high (>65000, signal saturation) and low
(<mean+2SD of negative controls) signal intensities were removed from the analysis.
Within-array normalisation was done using MLDA package (49) tailored for DMH datasets.
We removed samples where more than 10% of the probes had poor quality on both duplicate
arrays from the analysis. The DMH data pre-processing procedure is detailed in
Supplementary method 1. DMH ratio is the ratio of the signals from McrBC mock digested
and McrBC digested samples. The DMH dataset is available at GEO (accession ID:
GSE23240).
Target selection on Agilent custom-designed micorarray
Genes involved in the Wnt signalling pathway were collected from Kyoto Encyclopedia of
Genes and Genomes (KEGG) (entry ID: hsa04310) (50). Promoter CGIs within 2kb of the
transcription start site of the genes were obtained from UCSC database (51) and from a
genome-wide prediction of CGIs (52) as a supplementary set, both of which fulfil the
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mathematical model proposed by Gardiner-Garden to define a CGI: CG content greater than
50%, length of sequence is over 200bp and ratio of observed to expected CpGs is larger than
0.6 (53). The genome positions of targets are specified by Human Mar. 2006 (NCBI36/
hg18) assembly. Out of 148 genes in the Wnt pathway, 137(92.6%) had a CpG island within
2Kb of the promoter and these are represented by 302 MseI fragments (130-6000bp)
analysed by DMH.
The Cancer Genome Atlas (TCGA) dataset
The level 2 expression dataset on Affymetrix HGU133A microarrays and level 3
methylation dataset on Illumina HumanMethylation27 Beadchip of serous tumours were
obtained from TCGA data portal (http://cancergenome.nih.gov/dataportal), consisting of 311
high-grade serous tumours.
The expression microarray data have been pre-processed and normalised across the samples,
and methylation data have been summarized as β value which was calculated as M/(M+U),
where M is the signals of methylation bead type and U is the signals of unmethylation bead
type of the targeted CpG site (see http://tcga-data.nci.nih.gov/docs/TCGA_Data_Primer.pdf
and Supplementary method 2 for details)
Statistical analysis
All statistical analyses were performed in R (version 2.10.1) and SPSS (version 18.0).
Sample Size and Statistical Power Estimation—The initial screening set consisted of
DMH data from 120 tumours, with 111 subsequently shown to have suitable data quality
and 102 patients had disease progression (see results). To estimate approximate statistical
power of this screening set prior to analysis, we assumed 5% of the loci examined in the
Wnt pathway were true positives and split patients into two groups based on the median
methylation level at each locus (in the subsequent analysis methylation levels have been
treated as continuous variables, meaning we are underestimating the study power). With a
hazard ratio at 1.75 and false discovery rate (FDR) (54) less than 50%, we estimated the
average power of the screening study to be 80% (Supplementary Method 3).
The subsequent validation study was analysed by DMH a year later. Calculation of the
statistical power for the sample size planned (n=50) assumed the true positive loci rate was
40% (following on from the FDR rate observed in the screening set at p<0.05) and using a
FDR of 10%. Sample size calculations were carried out using the observed hazard ratios per
unit change and observed variable variances from the screening data set. Testing was 1-
sided as associations of interest will be in the same direction as in the screening set. The
validation power achieved for the largest observed effect size in the screening set was 88%,
but only 30% for the median observed effect size. Among the 5 loci with FDR<10% from
the screening set the median power was 70% (Supplementary Method 3).
Determination of Methylation Frequency in EOC—Methylation of loci for
estimating frequency of methylation in EOC were defined by DMH ratios of multiple probes
targeting the same locus being significantly greater than unmethylated controls from
chromosome 16 and the mitochondrial genome. The unmethylated controls were selected
from the mitochondrial genome and low CG density region from chromosome 16
(59,000,000- 61,000,000) that lacks McrBC recognition site (49). In average, each MseI
fragment was covered by 12 probes and by at least 7 probes. To examine what the
percentage of tumours in SGCTG cohort are methylated at the loci we examined, one-sided
Mann-Whitney U test was used to compare the methylation levels of multiple probes
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targeting the same MseI fragment to those of unmethylated controls (n=93) designed on the
microarray. The significance level was set at p<0.0003 based on Bonferroni correction.
Survival Analysis—The workflow of the survival analysis is illustrated in Supplementary
Figure 1. Cox proportional hazard model was used to examine for association between
methylation and patient survival. The DMH ratios of multiple probes targeting the same
locus (MseI fragment) were averaged. The mean value of methylation at the locus in
duplicates was used as a continuous variable in the Cox model. The association between
methylation and PFS was examined by univariate Cox model first, and then multivariate
analysis was performed to evaluate the independence of loci identified from clinical
parameters. The variables applied for adjustment in multivariate analysis included
histological type, FIGO stage, grade and age. The significance of estimated hazard ratios
was calculated using the Score test.
To determine the best predictors of PFS in patients with late-stage (stage III and IV) ovarian
cancer, a multivariate Cox model was constructed using the forward stepwise method based
on likelihood ratio statistics with a probability of 0.05 for entry and 0.10 for removal
(Supplementary Method 4). Among the variables including clinical parameters and
validated, independent methylation markers only two methylation markers meet the entry
criteria, thus selected into the model in this study (see results). Subsequently, a methylation
index (MI) was calculated using the selected covariates from this model. Leave-One-Out
Cross Validation (LOOCV) was performed to evaluate the predictive value of this
multivariate Cox model (Supplementary method 5).
Kaplan-Meier curves were used to show the progression free survival in the patients with
high/low methylation at promoter CGI, as well as those with high/low MI. Since average
methylation frequency of the Wnt pathway genes observed is approximately 25%, the third
quartile was used as the cut-point to define high/low methylation. Kaplan-Meier survival
curves of two groups were compared by the log-rank test (two-sided). The significance of
log-rank test of two groups with high/low MI determined by the third quartile was assessed
by a permutation test applied to the entire variable selection and model fitting process.
The correlation between response and promoter methylation in the Wnt pathway was tested
by logistic regression. This is restricted to patients with measurable disease at baseline.
Patients were classified as responders (complete or partial response) or non-responders
(stable disease or progressive disease) according to RECIST 1.0 criteria.
External validation of prognostic value of biomarkers identified from SGCTG cohort was
done in TCGA cohort using methylation level (β value)/expression as a continuous variable
in univariate analysis, then multivariate analysis was performed to adjust the hazard ratio of
disease progression/relapse in every unit increase of expression data by clinical parameters
(stage, grade and age) in this cohort. The direct association between methylation and
expression was evaluated by Spearman correlation.
Results
Patient characteristics
Epithelial ovarian tumours prospectively collected through a cohort study, were analysed by
differential methylation hybridisation (DMH) at 302 Wnt pathway associated loci, as
defined by KEGG (entry ID: hsa04310) (50). Mucinous and clear cell cancers were
excluded due to their different clinical outcome from more common serous and
endometrioid EOC (37, 38). In an initial screening stage, from 120 ovarian tumour samples
analysed by DMH, four samples were excluded from subsequent analysis due to poor
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quality of signal intensities in over 10% of probes in the duplicates and five samples were
excluded as methylation controls did not reach acceptance criteria. Therefore, 111 tumours
remained in the analysis. Assuming a hazard ratio of 1.75 and false discovery rate (FDR)
(54) less than 50%, then the estimated average power of the screening study is 0.8
(Supplementary Method 2). In a subsequent validation stage, 59 further tumours collected
through the same protocol were examined. Eleven samples were excluded due to not
reaching acceptance criteria, so 48 tumours remained in the analysis. Among the loci with
FDR<10% from the screening set the median power of the validation study was about 70%.
The genes in the Wnt pathway frequently methylated (>5%, i.e. methylated in over 5% of
tumours) in ovarian cancer and unmethylated in PBMC are shown in Supplementary Table
1. Following the REMARK recommendations (55), we present full details of clinical
parameters in Supplementary Table 2 and their relationship to patient outcome in
Supplementary Table 3 and 4.
Methylation in the Wnt pathway and progression free survival
To evaluate the association between methylation at promoter CGIs of the Wnt pathway and
tumour progression, we used average DMH ratios as a continuous variable in the univariate
Cox model with PFS as the endpoint (see methods). In the screening study we identified
methylation of 20/302 loci at promoter CGIs of 17 genes that may be associated with PFS
(p<0.05), with five loci at genes FZD4, DVL1, CCND1, CCND3 and NKD1 significant at
FDR<10% after multiple test correction (see univariate survival analysis in Table 1). In an
independent patient cohort (n=48), 11 out of the 20 loci identified in the screening stage
were still prognostic, p≤0.05 and FDR≤10% (Table 2).
The odds ratios of 11 loci identified as having p≤0.05 and FDR≤10% in univariate analysis
from the validation study were adjusted by age, stage, grade and histological type and the
patients were stratified into three groups who either received platinum alone, combination of
platinum and taxane, or other platinum-based treatment.
Hypermethylation at 7 loci was associated with increased hazard of disease progression
independent from clinical parameters: CGIs at FZD4, DVL1, AXIN1 and LRP5 (adjusted
p<0.05) and CGIs at NKD1, ROCK1 and NFATC3 (adjusted 0.05<p<0.06) (see multivariate
survival analysis in Table 3 and Figure 1A-G). Of the 7 loci, patients with increased
methylation level at gene DVL1, FZD4 and NKD1 also had higher risk of death (p<0.05,
FDR≤20%) (Table 4).
DNA methylation at the 6 loci associated with poor PFS were assessed for any relationship
with patients’ response to first line platinum-based chemotherapy. In order to maximize the
numbers of patients with response data, this was examined in the screening and validation
sets combined, therefore, the average DMH ratio of each locus was transformed to a Z score
(standardised average DMH ratio of each locus within each study). Increased methylation at
DVL1 and NFATC3 was correlated with poor response. The odd ratio of the patients with
progressive or stable disease (n=29) to the patients with partial or complete response (n=54)
in every unit increase of methylation Z score is 1.7 (95% CI 1.1-2.8, p=0.026, FDR<10%)
and 1.6 (95% CI 1.0-2.6, p=0.032, FDR<10%) for DVL1 and NFATC3, respectively.
Wnt pathway methylation index in the late-stage ovarian tumours
To identify the best methylation predictors of PFS in the ovarian tumours from both
screening and validation sets, the average DMH ratio of each locus was transformed to a Z
score. We excluded 10 Stage I tumours from 159 tumours since these may be biologically
distinct entities and patients with early-stage ovarian cancer have much better clinical
outcome than patients with late-stage cancer. From the Z scores of 150 patients with late-
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stage EOC (stage III and IV), we constructed a multivariate Cox model, of which the
covariates were selected by likelihood ratio (LR) forward stepwise algorithm from clinical
parameters (age, stage, grade and histological type) and promoter methylation at FZD4,
DVL1, NKD1, ROCK1, LRP5, AXIN1 and NFATC3 (see Supplementary method 4). The
final model includes DVL1 (HR = 1.24; 95% CI 1.05-1.46; p=0.01) and NKD1 (HR = 1.28;
95% CI 1.04-1.57; p=0.02) as the two best predictors. The hazard ratio (HR) represents the
relative risk per unit increase in Z score. The remaining variables including clinical
parameters and 5 methylation biomarkers were not selected into the model due to not
meeting the entry criteria in forward stepwise method (see Methods), i.e. the association
between PFS and methylation at FZD4, ROCK1, LRP5, AXIN1, NFATC3 as well as other
conventional prognostic factors: grade, stage, age and histological type do not provide
additional prognostic information beyond that provided by DVL1 and NKD1. A methylation
index (MI) calculated from this model ( MI = 0.25 × Z NKD 1 + 0.22 × Z DVL1, Z denotes Z
score) can identify two distinct prognostic groups using the third quartile of the index as the
cut-off (HR=2.09; 95%CI (1.39, 3.15); log rank test p=2.42×10−4; permutation test p<0.005)
(Figure 1H). Leave-One-Out Cross Validation (LOOCV) was used to assess the predictive
value of the multivariate Cox model in 150 late-stage EOCs (see Supplementary Figure 2). .
External validation of the biomarkers from Wnt pathways in TCGA study
To validate in a further independent tumour set the prognostic value of the 7 validated
methylation biomarkers that are independent from clinical parameters (at genes FZD4,
DVL1, NKD1, ROCK1, AXIN1, LFRP5 and NFATC3), we analysed associations between
PFS and methylation at these loci in data from a large (n=311) independent cohort of high-
grade serous ovarian tumours (see Method and Supplementary method 6) available through
The Cancer Genome Atlas (TCGA) Pilot study established by the NCI and NHGRI
(unpublished). The methylation data was generated using a different method from DMH:
analysis of bisulphite modified DNA by Illumina HumanMethylation27 BeadChip.
Individual CpG sites, either within exactly the same genomic location or within the same
promoter CGI of the genes identified in our study, are present on the HumanMethylation27
BeadChip, except at NKD1. Among the 6 loci examined, methylation of DVL1, ROCK1,
LRP5 and AXIN1 were still prognostic in this independent patient cohort (one-sided p<0.05,
FDR<10%, n=311), and methylation of FZD4 shows marginal correlation with PFS in this
patient cohort (one-sided p=0.06, FDR<10%) (see univariate PFS analysis in methylation in
Table 5).
Expression of genes associated with methylated loci and progression free survival
Promoter hypermethylation is frequently associated with gene inactivation (16), therefore,
we further examined the association between expression and PFS of the 7 linked candidate
genes as well as direct correlation between expression and methylation. This was examined
in the TCGA cohort (n=311). Among the 7 genes, NKD1 is not present on the Affymetrix
HGU133A expression microarray and lacks coverage of CpG sites on HumanMethylation26
BeadChip. For the remaining 6 genes, low expression of FZD4, DVL1 and ROCK1
indicated a higher risk of recurrent/progressed disease (FZD4: HR= 0.8; 95% CI 0.7-0.9;
adjusted p=0.002; DVL1: HR=0.8; 95% CI 0.6-1.0; adjusted p=0.035; ROCK1: HR=0.7;
95% CI 0.5-1.0; adjusted p=0.045), independent from stage, grade and age (see univariate
and multivariate PFS analysis in expression in Table 5). The reduced expression of FZD4,
DVL1 and ROCK1 correlating with increased hazard of disease progression is consistent
with promoter methylation leading to the down-regulation of the genes, although direct
inverse association between expression and methylation was only found at DVL1 (rs=−0.13,
p=0.023) and ROCK1 (rs =−0.25, p<0.001), but not at FZD4 (rs =0.02, p=0.766) by
Spearman correlation (see correlation between methylation and expression in Table 5).
Again consistent with the methylation data is that decreased expression of DVL1 was related
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to poor response to platinum-based chemotherapy in the TCGA cohort (PD+SD (n=36) vs.
PR+CR (n=217), OR =0.5, 95% CI 0.3-0.9, p=0.035).
Discussion
We examined DNA methylation at CGIs at the promoter regions of Wnt pathway genes, as
defined by KEGG (entry ID: hsa04310)(45), in 159 EOCs. Using average DMH ratio as a
continuous variable we identified 7 loci (FZD4, DVL1, ROCK1, NFATC3, AXIN1, LRP5
and NKD1) of which methylation was significantly associated with PFS in evaluation and
validation tumour cohorts and are independent from known clinical prognostic features.
As with any microarray experiment, systematic bias can be introduced from any of the
multiple steps of DMH: such as, DNA preparation, hybridisation and image scan. In
particular, DMH based on McrBC restriction enzyme, involves extra steps of digestion,
ligation and PCR amplification. Therefore, the reproducibility of technical duplicates was
evaluated using R2 (coefficient of determination, ranging from 0 to 1) to estimate the
variations introduced in DMH assays. After background correction, with-array normalisation
and feature selection, the average R2 of duplicate arrays in the screening set (n=111) and in
the following validation set (n=48) was very close to 1, 0.92 (n=111; mean±SD: 0.92±0.04)
and 0.96 (n=48; mean±SD: 0.96±0.02), respectively. This indicates the bias in our DMH
assays was small, especially after appropriate data pre-processing. In addition, prior to
conducting the survival analysis of the Wnt pathway, we observed a good correlation
between existing bisulphite pyrosequencing methylation data at locus (chr14:
60174197-60174329) and average DMH ratio observed at this locus (Spearman correlation
rs =0.87, p<0.01) (Supplementary Figure 3), supporting the use of average DMH as a
continuous variable in the methylation analysis. We further examined two loci (DVL1 and
FZD4) by bisulphite pyrosequencing in the screening set of SGCTG cohort (see
Supplementary method 6), and found positive correlation between DMH assay and
bisulphite pyrosequencing at these two promoter CGIs (Spearman correlation: DVL1, rs
=0.35, p=0.001, n=79; FZD4, rs=0.19, p=0.037, n=91). This indicates the use of DMH assay
on custom-designed microarray with intensive coverage at promoter CGIs is reliable for
biomarker identification.
SFRP5 has been previously reported to correlate with poor response to platinum-based
chemotherapy (40). We found methylation at SFRP5 was weakly associated with PFS, but
not independent from clinical parameters (adjusted p=0.124, n=111), and had no correlation
with response to chemotherapy (OR=1.1, 95% CI (0.7, 1.6), p=0.791). Since it has been
shown that transcriptional silencing of SFRP5 is associated with promoter methylation (40),
we further examined if expression of SFRP5 was correlated with response to first line
platinum-chemotherapy in the TCGA dataset, but no significant association was observed.
However, we noted response was measured by both the reduction of tumour size and CA125
concentration in the previous study, while in our study response was measured by RECIST
1.0 criteria based on the shrinkage of tumour size. Furthermore, different composition of
tumour stage and histology type in the cohort studies might also cause the differences. We
observe that the prognostic value of FZD4, DVL1 and ROCK1 at two molecular levels,
increased methylation and decreased expression, are correlated with increased hazard of
disease progression in EOC. This indicates expression of these three genes might be tightly
regulated by promoter methylation. The interaction between individual Wnts and their
specific receptors is thought to dictate the type of downstream signalling pathways that are
activated. Accordingly, the Wnts have historically been divided into two classes: those that
signal through the ‘canonical’ (β-catenin dependent) or the ‘non-canonical’ (β-catenin
independent) signalling pathway (21). FZD4 is a member of the frizzled receptor family and
playsq a crucial role in corpus luteum formation and function in mouse ovary (20). FZD4 is
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required along with LRP5, and the absence of ROR2, for Wnt-5a dependent β-catenin
transcriptional activation (21). Three dishevelled genes, DVL1, DVL2 and DVL3 have been
identified in human. The Wnt3a-sensitive canonical pathway is particularly sensitive to
knock-down of either Dvl1 or Dvl3 (56). Thus, promoter CGI methylation of DVL1 and
FZD4 leading to down-regulation of the expression of these two genes could suppress the
‘canonical’ signalling pathways in EOC, while potentially activating the non-cannonical
pathways.
Although the majority of the samples from SGCTG cohort are serous ovarian tumours, a
small number of tumours were endometrioid (n=12). It has been reported that 16-38% of
ovarian enometrioid cases are deregulated in the Wnt pathway because of activating
mutation of β-catenin, which is a key player in the Wnt canonical pathway (57). Given the
prognostic value of 5 out of 7 independent methylation biomarkers found in SGCTG cohort
have been confirmed in the TCGA cohort which only contain high-grade serous ovarian
tumours we would argue that the presence of β-catenin mutation in endometrial cancers is
unlikely to be a major confounding factor.
Further investigation is required for the loci that did not show a direct correlation between
expression and methylation. As well as the limitations of microarray coverage, limited
statistical power and potential lack of appropriate transcription factors at the unmethylated
promoters, these analysis are mainly confounded by the tumour samples in the TCGA cohort
not being microdissected, which could influence TCGA expression data due to expression of
the genes in normal infiltrating tissues. It is also possible that the biomarkers identified are
heterogeneously methylated in the tumour tissue, i.e. differential methylation of those
biomarkers only exist in a subset of tumour (or normal infiltrating) cells, therefore, the
changes of expression of those genes in a subpopulation are masked by the general
expression levels in the entire tumour. A further limitation of the study is the low average
power of the analysis in the validation set (see Materials and Methods). However, 11 out of
20 independent biomarkers identified in the first screening set have been validated in the
second patient cohort. Nevertheless, those loci that have not been validated need further
investigation in a larger sample set.
Although multiple types of biomarkers have been shown the promise in ovarian cancer
prognosis, such as serum CA125 and HE4 (15), plasma lysophosphatidic acid (LPA) (58),
mRNA expression profiling (59, 60) and microRNAs (61), there are a number of advantages
of using DNA methylation as a clinical biomarker (62-65). Compared to protein-based
biomarkers, DNA methylation is amplifiable and can be detected easily by PCR-based
methods. Contrary to gene mutation, cancer-specific hypermethylation generally occurs in a
defined region usually in or near promoter region of the genes. In addition, the advantages of
DNA methylation over gene or microRNA expression are (1) it is fairly stable in vivo
(heritable in cell division and do not fluctuate in response to short-term stimuli) and ex vivo
(can survive routine processing for histopathology), (2) DNA methylation is readily detected
in body fluids, such as plasma, and (3) it is less influenced by normal cell contamination.
In conclusion, we have shown that methylation of multiple promoter CGIs in the Wnt
pathway is frequently observed in epithelial ovarian cancer and identified methylation of
key loci as significantly associated with PFS (CGIs at FZD4, DVL1, NKD1, ROCK1,
AXIN1, LRP5 and NFATC3) that are independent from clinical parameters. We have used
this data to construct a multivariate Cox model that incorporates two independent CGIs at
NKD1 and DVL1, which can identify two groups of patients with distinct PFS.
Methylation changes at the Wnt pathway will be relevant for patient stratification in future
clinical trials of ovarian cancer, particularly for novel drugs targeting the Wnt pathway (66).
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Statement of Translational Relevance
Epithelial ovarian cancer (EOC) is the most lethal of all the gynaecological cancers (1).
Patients with advanced disease have surgical cytoreduction followed by platinum-based
chemotherapy, but there is a low 5-year survival rate due to disease progression and the
acquisition of resistance to therapy (1-5). There is a need for biomarkers to assist our
understanding of the molecular basis of ovarian cancer progression and of sufficient
discriminatory prognostic power to be able to aid clinical management of this disease.
We have systematically examined promoter CpG island methylation at Wnt pathway
genes using differential methylation hybridisation of customised microarrays spanning
over 300 loci and identified loci associated with progression-free survival of patients that
are independent from known clinical prognostic factors. The data demonstrate the clinical
importance of epigenetic regulation of multiple promoter CpG islands at Wnt pathway
genes in ovarian cancer and their potential as predictive biomarkers in future clinical
studies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Kaplan-Meier plots of progression free survival
High/low methylation at A, FZD4 CGI, B: NKD1 CGI, C: DVL1 CGI, D: ROCK1 CGI, E:
AXIN1 CGI, F: LRP5 CGI, G: NFATC3 CGI. Combined analysis of the evaluation and
validation set shows that patients with hypermethylation at these loci have increased hazard
ratio of disease progression (p<0.05). The cut-off was determined by the third quartile in
156 patients (n=159, 3 patients have PFS missing). Time is from the patients received the
first line of chemotherapy. H, Kaplan-Meier plots of progression free survival in the patients
with high/low methylation index (MI) estimated from the multivariate Cox model including
DVL1 and NKD1 in late-stage ovarian cancer. The cut-off was determined by the third
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quartile in 147 patients (n=150, 3 patients have PFS missing). Time is from the patients
received the first line of chemotherapy.
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Table 1
Univariate progression free survival analysis of screening set: loci with p<0.05
genes
Univariate PFS analysis (n=111)
HR1 95% CI2 p value3 FDR4
FZD4 123.3 (8.9, 1701.30) <0.001*** <0.1&
CCND1$ 3.9 (1.8, 8.3) <0.001*** <0.1&
NKD1 31.4 (3.7, 268.3) 0.002** <0.1&
TAF8∥CCND3 0.5 (0.3, 0.8) 0.002** <0.1&
DVL1 12.1 (2.6, 55.5) 0.001** <0.1&
FRAT1 0.3 (0.1, 0.7) 0.005** 0.2
ROCK1 2263.1 (7.5, 681782.4) 0.008** 0.3
PPP2R2B 34.0 (2.4, 476.6) 0.009** 0.4
CTBP1$ 2.3 (1.2, 4.3) 0.015* 0.4
CCND1$ 48.6 (2.1,1108.6) 0.015* 0.4
NKD2 10.6 (1.5, 74.1) 0.017* 0.5
FZD9 7.4 (1.4, 41.0) 0.021* 0.5
EEFSEC∥RUVBL1 2.4 (1.2, 5.2) 0.021* 0.5
AXIN1 24.5 (1.4, 423.3) 0.028* 0.6
C4orf42∥CTBP1$ 1.9 (1.1, 3.3) 0.030* 0.6
WNT4 41.1 (1.3, 1282.7) 0.034* 0.6
LRP5 5.7 (1.1, 30.2) 0.041* 0.6
NFATC3 6.4 (1.1, 37.6) 0.042* 0.6
FRAT1 0.7 (0.6, 1.0) 0.040* 0.6
SFRP5 51.2 (1.1, 2386.6) 0.045* 0.6
Abbreviations: HR, hazard ratio; CI, confidence interval; FDR, false discovery rate
1
Hazard ratio per unit increase in DMH ratio (continuous variable) estimated from Cox proportional hazard regression model.-
2Confidence interval of the estimated hazard ratio.-
3p value of Score test (two-sided).-
4
multiple test correction based on 302 loci. -
&
FDR≤0.1;
*p≤0.05;
**p≤0.01;
***p≤0.001.
$
Different loci within the promoter region of CCND1/CTBP1 were identified as fulfilling the definition of a CGI.
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Table 2
Univariate progression free survival analysis in the validation set of loci with p<0.05 in screening set
genes
Univariate PFS analysis (n=48)
HR1 95% CI2 p value3 FDR4
FZD4 2.5 (0.9, 6.6) 0.034* <0.1&
CCND1$ 1.4 (0.6, 3.4) 0.225 0.2
NKD1 2.2 (0.9 5.2) 0.039* <0.1&
TAF8∥CCND3 1.3 (0.9, 1.8) 0.929 1
DVL1 4.3 (1.2, 15.0) 0.010* <0.1&
FRAT1 1.2 (0.7, 2.1) 0.787 0.9
ROCK1 4.3 (1.0, 19.4) 0.027* <0.1&
PPP2R2B 1.7 (0.1, 27.6) 0.357 0.4
CTBP1$ 1.3 (0.7, 2.4) 0.176 0.2
CCND1$ 3596.2 (17.0, 75887.8) 0.001* <0.1&
NKD2 1.9 (0.8, 4.4) 0.062 0.1&
FZD9 1.7 (0.9, 3.2) 0.057 0.1&
EEFSEC∥RUVBL1 1.7 (1.0, 2.7) 0.016* <0.1&
AXIN1 2.7 (0.9, 7.6) 0.032* <0.1&
C4orf42∥CTBP1$ 1.5 (0.9, 2.6) 0.074 0.1&
WNT4 2.6 (1.1, 6.2) 0.016* <0.1&
LRP5 2.6 (1.0, 6.2) 0.020* <0.1&
NFATC3 5.1 (1.3, 20.0) 0.010* <0.1&
FRAT1 1.2 (0.9, 1.5) 0.910 1
SFRP5 2.2 (0.9, 5.3) 0.042* <0.1&
Abbreviations: HR, hazard ratio; CI, confidence interval; FDR, false discovery rate
1
Hazard ratio per unit increase in DMH ratio (continuous variable) estimated from Cox proportional hazard regression model.-
2Confidence interval of the estimated hazard ratio. -
3p value of Score test (one-sided). -
4
multiple test correction based on 20 loci.
&
FDR≤0.1;
*p≤0.05;
**p≤0.01.
$
Different loci within the promoter region of CCND1/CTBP1 were identified as fulfilling the definition of a CGI.
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Table 3
Multivariate progression free survival analysis of loci significantly associated with PFS in univariate analysis
genes
Multivariate PFS analysis (n=111)
HR1 95% CI2 adjusted p value3
FZD4 64.5 (3.4, 1243.8) 0.006*
NKD1 10.2 (0.9, 113.4) 0.059+
DVL1 8.3 (1.7, 39.1) 0.008*
ROCK1 285.4 (1.0, 82977.6) 0.051+
CCND1 4.6 (0.5, 37.9) 0.161
EEFSEC∥RUVBL1 1.7 (0.8, 3.7) 0.184
AXIN1 44.9 (2.0, 1004.6) 0.016*
WNT4 15.6 (0.4, 670.8) 0.152
LRP5 6.8 (1.3, 36.6) 0.026*
NFATC3 6.6 (1.0, 44.9) 0.052+
SFRP5 26.8 (0.4, 1774.0) 0.124
Abbreviations: HR, hazard ratio; CI, confidence interval
1
Hazard ratio per unit increase in DMH ratio (continuous variable) estimated from Cox proportional hazard regression model.-
2Confidence interval of the estimated hazard ratio. -
3p value adjusted by histology, grade, stage and age. Age was used as a continuous variable and histology, grade and stage were used as categorical
variables.
+p<0.l
*p≤0.05;
**p≤0.01;
***p≤0.001.
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Table 4
Univariate overall survival analysis of loci significantly associated with PFS
genes
Univariate Overall Survival (OS) (n=111)
HR1 95% CI2 p value3 FDR4
FZD4 49.4 (2.5, 964.3) 0.01* 0.1&
NKD1 21.3 (1.5, 299.2) 0.023* 0.2$
DVL1 14.0 (2.6, 75.0) 0.002*** <0.1&
ROCK1 8.6 (0, 5642.9) 0.516 1
NKD2 1.3 (0.2,11.2) 0.804 1
FZD9 3.3 (0.5, 23) 0.224 1
CCND1 33.4 (0.8, 1382.2) 0.065+ 0.5
EEFSEC∥RUVBL1 1.4 (0.6, 3.4) 0.505 1
AXIN1 3.1 (0.1, 85.4) 0.506 1
C4orf42∥CTBP1 1.4 (0.6, 3.4) 0.505 1
WNT4 5.9 (0.1, 335.6) 0.388 1
LRP5 4.6 (0.6, 33.8) 0.13 0.9
NFATC3 4.5 (0.6, 35.2) 0.148 0.9
SFRP5 1.1 (0, 110.1) 0.967 1
Abbreviations: HR, hazard ratio; CI, confidence interval; FDR, false discovery rate.
1
Hazard ratio per unit increase of DMH ratio (continuous variable) estimated from Cox proportional hazard regression model.-
2Confidence interval of the estimated hazard ratio.-
3p value of Score test.-
4
multiple test correction in the validation study based on 14 validated DNA methylation biomarkers.
$
FDR≤0.2;
&
FDR≤0.1;
+p≤0.1;
*p≤0.05;
**p≤0.01;
***p≤0.001
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